Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Japan
Biotech
Boehringer places ph. 1 study on hold to examine ‘safety event’
Boehringer has suspended a phase 1 trial of an investigational oral small molecule drug in Japan while it seeks to understand a “safety event.”
Marissa Russo
Aug 21, 2026 4:50am
Japan, South Korea challenge the West in research rankings
Jun 15, 2026 2:35pm
Cell therapy biotech could end Tokyo IPO drought with $92M offer
Feb 17, 2026 11:06am
JPM26: Chugai chases new science and name recognition
Jan 16, 2026 5:28am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Kyorin pens $105M pact for Japan rights to Hinge's lupus drug
Oct 1, 2025 6:40am
